Question explored with the scientific record
What is the evidence for rsv vaccination in elderly. Benefits and risks
The short version: the RSV vaccines for elderly adults reduce lab-confirmed lower respiratory tract infections over one season, but no trial in the evidence shows a reduction in all-cause mortality, and long-term safety data is absent.
The evidence comes from two Phase III trials funded by manufacturers. The RSVPreF3 OA (GSK) trial randomized about 25,000 adults 60+ and reported 67–83% efficacy against RSV-related lower respiratory tract infection [6]. The Nano-RSV trial randomized 400 adults 60+ and reported a 46% reduction in RSV LRTI incidence (8.5% vs 15.2% in placebo) and a halving of RSV-related hospitalizations (3.2% vs 6.5%) [8]. Both trials used hard clinical endpoints, which is better than surrogate antibody titers. But neither trial compared vaccinated to truly unvaccinated people over multiple seasons, and neither reported all-cause mortality or serious adverse events beyond the short follow-up window.
The safety data is thin. The Nano-RSV trial reported injection-site and systemic reactions at rates similar to placebo, with 2 severe adverse events in the vaccine group and 1 in placebo [8]. That is a single trial with 400 people, far too small to detect rare harms. The Italian cross-sectional study of 453 vaccinated elderly reported high trust in vaccines but no safety follow-up at all [4]. No study in the evidence followed participants for longer than one RSV season. No study compared vaccinated to unvaccinated over multiple years. The most informative safety design was never run.
| Outcome | Vaccine group | Placebo group | Relative reduction |
|---|---|---|---|
| RSV LRTI (Nano-RSV) | 8.5% | 15.2% | 46% |
| RSV hospitalization (Nano-RSV) | 3.2% | 6.5% | 51% |
| RSV LRTI (RSVPreF3 OA) | Not reported in evidence | Not reported in evidence | 67–83% |
My call: the vaccines likely reduce RSV-related respiratory illness over one season in elderly adults, but the evidence does not show a mortality benefit, does not include long-term safety data, and comes from manufacturer-funded trials with no multi-year unvaccinated comparison group. Confidence: moderate for short-term efficacy against mild illness, low for safety beyond the first season.
Sources examined 8
-
Enzyme-Linked Immunospot Assay for Detection of Human Respiratory Syncytial Virus F Protein-Specific Gamma Interferon-Producing T Cells
This study developed and qualified a sensitive and robust enzyme-linked immunospot (ELISPOT) assay for measuring RSV F-specific IFNγ-producing T cell responses in elderly adults, addressing the challenges of immunosenescence and the need for effective RSV vaccines in this popula…
DOI: 10.1128/cvi.00736-13 -
Respiratory syncytial virus infection in older persons
This study investigates the epidemiology, diagnosis, immunity, and vaccine responses related to respiratory syncytial virus (RSV) infections in elderly populations, highlighting the significant morbidity and mortality associated with RSV in this demographic.
DOI: 10.1016/s0264-410x(98)00142-x -
Current State and Challenges in Developing Respiratory Syncytial Virus Vaccines
This review surveys the current RSV vaccine landscape, detailing four main vaccine formats (particle-based, vector-based, subunit, and live-attenuated) and monoclonal antibodies, summarizing clinical trial results, safety profiles, and implications for vaccination strategies in …
DOI: 10.3390/vaccines8040672 -
Characteristics of the First Italian Older Adults Vaccinated with an Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine
This cross-sectional study characterizes the first cohort of Italian older adults vaccinated with the adjuvanted RSVPreF3 OA vaccine in Liguria (n=453), detailing their sociodemographic and clinical characteristics, high prevalence of comorbidities, uptake of other vaccines, and…
DOI: 10.3390/medicina61010067 -
B Cell Immunosenescence
A comprehensive review of how aging affects B cell development, subsets, antibody production, and vaccine responses, highlighting inflammaging, obesity as a modulator, CMV and microbiome influences, and the emergence of proinflammatory B cell types that diminish humoral immunity…
DOI: 10.1146/annurev-cellbio-011620-034148 -
Efficacy of influenza vaccine in adults. Systematic review
High-dose quadrivalent influenza vaccines and vaccines with natural adjuvants enhance immunogenicity and reduce hospitalizations in older adults, while co-administration with other vaccines is generally safe and effective.
DOI: 10.62486/mo202334 -
A Review of Insights on Vaccination Against Respiratory Viral Infections in Africa: Challenges, Efforts, Impacts, and Opportunities for the Future
This narrative review synthesizes current evidence on vaccination efforts against influenza, RSV, and SARS-CoV-2 in Africa, highlighting vaccine effectiveness, coverage, barriers, and opportunities for local production and policy to improve immunization across the continent.
DOI: 10.3390/vaccines13090888 -
Efficacy of a Novel Nanoparticle RSV Vaccine in Preventing Infection in Older Adults: Phase III Clinical Trial
Nano-RSV, a liposome-encapsulated prefusion F protein nanoparticle RSV vaccine, reduces lab-confirmed RSV LRTI incidence and RSV-related hospitalizations in adults 60+ with a safety profile similar to placebo.
DOI: 10.54963/ti.v9i4.1004